-
Global Biotechnology & Pharmaceutical Markets3 weeks agoImmune Cell Atlas Charts How People’s Aging Paths Diverge
Two people born on the same day can have immune systems that age differently. An immune cell atlas shows that a ratio between two cell types...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoSaudi Arabia’s biotech momentum: inside RGMBS 2026
Today, we are joined by Abdulaziz Aldayel, from the King Abdullah International Medical Research Center to discuss the Riyadh Global Medical Biotechnology Summit. The post Saudi...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoMFN model is an elephant in a mousehole, PhRMA says
BIOCENTURY | POLITICS, POLICY & LAWMFN MODEL IS AN ELEPHANT IN A MOUSEHOLE, PHRMA SAYSLawsuit challenges legality of GLOBE and similar reference-pricing Medicare models
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoHHS launches new plan to strengthen vaccine injury research, reporting
Spearheaded by vaccine skeptic Robert F. Kennedy Jr., the initiative will involve a new NIH clinic, an updated monitoring system and reimbursements for doctors who report...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoMerck barred from making subcutaneous Keytruda in 8 European countries
With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoPhRMA sues Trump administration over GLOBE rebate scheme
PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoHalozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoSTAT+: Merck suffers a setback in Europe over its new Keytruda formulation
In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoTCG X set to invest $600M from dedicated Asia fund
BIOCENTURY | FINANCETCG X SET TO INVEST $600M FROM DEDICATED ASIA FUND‘Full circle’ moment for the firm’s Chen Yu
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoArriVent collapses on disappointing lung cancer data
More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
